Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

2.844 -0.256 (-8.26%)
Streaming Delayed Price Updated: 10:27 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Shattuck Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming December Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - October 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
NEW YORK, NY - (NewMediaWire) - October 03, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - October 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline ↗
Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.